In recent months, Bausch + Lomb reported solid quarterly results while facing pressure on free cash flow and carrying a sizeable debt load that could constrain financial flexibility. A separate update ...

There's a good reason why Bausch Health shares are experiencing yet another pullback. A recent clinical trial setback points to further trouble ahead. Buying on this latest round of weakness could ...

Bausch Health Companies (NYSE: BHC) shares have struggled for many year, and 2026 is not currently off to a good start. Since the start of the year, Bausch Health has fallen by 17%. There are several ...

A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan failed not just one but two phase 3 trials. The two phase 3 RED-C clinical ...

A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a ...

Bausch Health Companies (BHC) has recently drawn attention after its shares closed at $6.65, with short term returns showing a 2.1% one day decline and a 10.7% drop over the past week. See our latest ...

Brent Saunders, Bausch + Lomb Chairman and CEO, joins 'Mad Money' host Jim Cramer to talk investing in TikTok ads, its product pipeline, industry consolidation, and more. Got a confidential news tip?

Bausch + Lomb has partnered with the glaucoma community once again, launching its fifth annual fundraising challenge and sponsoring an awareness campaign in one of its priority therapeutic areas.

Bausch + Lomb is taking out roughly $2.8 billion in new loans to refinance its debt. The eye health company, a subsidy of Bausch Health Cos., said Friday that it was amending its credit agreement to ...

In recent days, Bausch Health Companies launched an offer to exchange up to US$1.6 billion of its 4.875% and 11.00% Senior Secured Notes due 2028 for new 10.00% Senior Secured Notes due 2032, with ...

Bausch + Lomb (NYSE:BLCO) announced Q3 2025 earnings and revenue that topped expectations, supported by growth across its business segments. The company also raised portions of its full-year outlook, ...

(a) The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current ...